NCT03989466View on ClinicalTrials.gov

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions
Recurrent T-Cell Prolymphocytic LeukemiaT-Cell Prolymphocytic Leukemia
Interventions
BIOLOGICAL

Alemtuzumab

Given IV

DRUG

Itacitinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03989466 - Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | Biotech Hunter | Biotech Hunter